Despite constitutive expression of NF-κB in cancers, SENP2 expression is found silenced, indicating additional epigenetic mechanisms operating in silencing of SENP2 expression, which could therefore serve as attractive targets for treating bortezomib resistant MM. This evidence concerns the gene SENP2 and Miyoshi myopathy.